Distribution and correlates of lipoprotein-associated phospholipase A 2 in an elderly cohort: The cardiovascular health study

Journal of the American Geriatrics Society

Volumn 56, Issue 5, 2008, Pages 792-799

  Furberg, Curt D ^a   Nelson, Jeanenne J ^b   Solomon, Cam ^c   Cushman, Mary ^d   Jenny, Nancy Swords ^d   Psaty, Bruce M ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Lp PLA2; Older adults

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPOPROTEIN;

AGED; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; Q WAVE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; ATHEROSCLEROSIS; BODY MASS INDEX; CARDIAC OUTPUT, LOW; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE; LONG QT SYNDROME; MALE; REFERENCE VALUES; RISK FACTORS; STATISTICS AS TOPIC; TRIGLYCERIDES;

EID: 43249125990     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2008.01667.x     Document Type: Article

References (35)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 1695.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002 105 : 1135 1143.
3. Stafforini DM, Elstad MR, McIntyre TM et al. Human macrophages secrete platelet-activating factor acetylhydrolase. J Biol Chem 1999 265 : 9682 9687.
4. Asano K, Okamoto S, Fukunaga K et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999 261 : 511 514.
5. 2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006 26 : 2523 2529.
6. 2 as an independent predictor of coronary heart disease. N Engl J Med 2000 343 : 1148 1155.
7. 2, platelet-activating factor acetylhydrolase: A potential new risk factor for coronary artery disease. Atherosclerosis 2000 150 : 413 419.
8. 2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 2001 38 : 1302 1306.
9. Blankenberg S, Stengel D, Rupprecht HJ et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: Results of a cross-sectional analysis. J Lipid Res 2003 44 : 1381 1386.
10. 2, high-sensitivity c-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 2004 109 : 837 842.
11. Ballantyne C, Hoogeveen R, Bang H et al. Lipoprotein-associated phospholipase A2, high sensitive C-reactive protein and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Arch Intern Med 2005 165 : 2479 2484.
12. 2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population. Results from the 14-year follow-up of a large cohort from Southern Germany. Circulation 2004 110 : 1903 1908.
13. Brilakis ES, McConnell JP, Lennon RJ et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005 26 : 137 144.
14. 2 mass and activity with calcified coronary plaque in young adults. The CARDIA Study. Arterioscler Thromb Vasc Biol 2005 25 : 216 221.
15. 2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam Study. Circulation 2005 111 : 570 575.
16. 2: Distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007 190 : 388 396.
17. Winkler K, Winkelmann BR, Scharnagle H et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors. The Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2005 111 : 980 987.
18. O'Donoghue M, Morrow DA, Sabatine MS et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (Pravastatin OratorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation 2006 113 : 1745 1752.
19. Corsetti JP, Rainwater DL, Moss AJ et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006 52 : 1331 1338.
20. Koenig W, Twardella D, Brenner H et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006 26 : 1586 1593.
21. Fried LP, Borhani NO, Enright P et al. The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1991 1 : 263 276.
22. Tell GS, Fried LP, Hermanson B et al. Recruitment of adults 65 years and older as participants in the cardiovascular health study. Ann Epidemiol 1993 3 : 358 366.
23. Cushman M, Cornell ES, Howard PR et al. Laboratory methods and quality assurance in the cardiovascular health study. Clin Chem 1995 41 : 264 270.
24. Shlipak MG, Fried LF, Crump C et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003 107 : 87 92.
25. Breiman L, Cutler A. Random Forests. Technical Report, Statistics Department, University of California at Berkley, 2001 [on-line]. Available at Accessed August 16, 2006.
26. 2. Arterioscler Thromb Vasc Biol 2007 27 : 2236 2243.
27. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis. Biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005 25 : 923 931.
28. van Vark L, Kardys I, Bleumink GS et al. Lipoprotein-associated phospholipase A2 activity and risk of heart failure: The Rotterdam Study. Eur Heart J 2006 27 : 2346 2352.
29. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: An overview. Heart 2004 90 : 464 470.
30. Gottdiener JS, Arnold AM, Aurigemma GP et al. Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2000 35 : 1628 1637.
31. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998 54 : 627 636.
32. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998 32 : 107 114.
33. 2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 2007 27 : 1411 1416.
34. 2: A new kid on the block. Clin Chem 2006 52 : 1645 1650.
35. Häkkinen T, Luoma JS, Hiltunen MO et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999 19 : 2909 2917.